Prescription GLP-1 treatments have been tested in large, long-running clinical trials involving thousands of participants: Semaglutide 2.4 mg (Wegovy) participants lost an average of around 1521% of their body weight over 6872 weeks in the STEP trials Tirzepatide (Mounjaro) the SURMOUNT trials showed average weight loss of 2025% of starting body weight at the highest dose over 72 weeks These results come from rigorously controlled studies with safety monitoring, dose titration, and long-term follow-up
Vitamin B12 deficiency has occurred in breast-fed infants of vegetarian mothers whose diets contain no animal products (e.g., eggs, dairy), even though the mothers had no symptoms of deficiency at the time
however, patients with severe neurological complications or critically low B12 status should be treated with i.m
Semaglutide also helps weight loss through other actions that do not depend on making sugar low: It reduces appetite and increases fullness by acting on satiety centres in the brain It slows stomach emptying, so you feel full sooner and longer So, in a non-diabetic person, the body still has normal safety systems, and semaglutide mainly helps by reducing calorie intake, not by forcing sugar down
For the past two years, as the demand for GLP-1 receptor agonists like Semaglutide and tirzepatide exploded, an alternative market quietly flourished
When it hits: Worst in the morning, with slight improvement as the day progresses